Matthew H G Katz

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
  2. pmc Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
    Matthew H G Katz
    Department of Surgery, The University of California, Orange, CA, USA
    Ann Surg Oncol 17:1794-801. 2010
  3. doi request reprint Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg 248:1098-102. 2008
  4. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
  5. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
  6. doi request reprint Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Surg Oncol 18:3615-22. 2011
  7. doi request reprint Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
  8. pmc Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
  9. doi request reprint A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma
    Christina L Roland
    Division of Surgery, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:2056-63. 2012
  10. pmc Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    HPB (Oxford) 14:506-13. 2012

Collaborators

Detail Information

Publications33

  1. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  2. pmc Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
    Matthew H G Katz
    Department of Surgery, The University of California, Orange, CA, USA
    Ann Surg Oncol 17:1794-801. 2010
    ..We evaluated CA 19-9 as a marker of therapeutic response, completion of therapy, and survival in patients enrolled on two recently reported clinical trials...
  3. doi request reprint Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg 248:1098-102. 2008
    ..To describe our approach to resection of pancreatic head cancers, which involve 1 or both of the first-order branches of the superior mesenteric vein (SMV)...
  4. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
    ..By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy...
  5. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
    ..To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma...
  6. doi request reprint Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Surg Oncol 18:3615-22. 2011
    ..We conducted a phase II trial to assess the survival duration and quality of life of patients who received adjuvant interferon-based chemoradiation for pancreatic adenocarcinoma after pancreaticoduodenectomy...
  7. doi request reprint Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
    ..There is no optimal treatment schema for this distinct stage of disease, so the role of surgery is undefined...
  8. pmc Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
    ..Following potentially curative resection at this centre, patients with pancreatic adenocarcinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study sought to evaluate its diagnostic yield...
  9. doi request reprint A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma
    Christina L Roland
    Division of Surgery, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:2056-63. 2012
    ..However, the use of the LNR to predict distant recurrence risk remains unknown. The purpose of this study was to determine if the LNR is associated with distant recurrence risk...
  10. pmc Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    HPB (Oxford) 14:506-13. 2012
    ..The relationships between extent of hepatectomy, postoperative VTE and bleeding events were evaluated using the National Surgical Quality Improvement Program (NSQIP) database...
  11. doi request reprint Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:2197-203. 2013
    ..Few data exist to guide oncologic surveillance following curative treatment of pancreatic cancer. We sought to identify a rational, cost-effective postoperative surveillance strategy...
  12. doi request reprint Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors
    Maria Q B Petzel
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:4078-84. 2012
    ....
  13. doi request reprint Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5749-56. 2012
    ..In this study, the authors sought to determine the rate at which neoadjuvant therapy is associated with a reduction in the size or stage of borderline resectable tumors...
  14. doi request reprint Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival
    Ching Wei D Tzeng
    Department of Surgery, University of Kentucky, Lexington, KY, USA
    J Gastrointest Surg 18:16-25. 2014
    ..NT sequencing is a practical treatment strategy, particularly for patients at high biological or perioperative risk. ..
  15. pmc Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Arch Surg 147:513-9. 2012
    ..To calculate conditional survival estimates for patients with pancreatic adenocarcinoma...
  16. doi request reprint Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification
    Ching Wei D Tzeng
    Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
    J Gastrointest Surg 18:146-56. 2014
    ..This study was designed to analyze the incidence and risk factors for post-pancreaticoduodenectomy (PD) morbidity/mortality in a multi-institutional cohort of BR-C patients...
  17. pmc Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection
    Ryan M Thomas
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:1696-704. 2012
    ..Resection of certain recurrent malignancies can prolong survival, but resection of recurrent pancreatic ductal adenocarcinoma is typically contraindicated because of poor outcomes...
  18. doi request reprint Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 215:e11-8. 2012
    ..The technical approaches we have described here can be used as a basic foundation for operative safety and efficiency during these challenging operations...
  19. pmc Current status of adjuvant therapy for pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 15:1205-13. 2010
    ..Well-designed prospective trials are needed to define the optimal adjuvant or neoadjuvant therapy strategy for these patients...
  20. doi request reprint Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 207:106-20. 2008
  21. doi request reprint Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:337-44. 2011
    ..Standardization of surgical and pathologic techniques is crucial to the interpretation of studies evaluating adjuvant therapies for pancreatic cancer (PC)...
  22. doi request reprint Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery
    Brian Badgwell
    Department of Surgical Oncology, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    J Surg Oncol 108:182-6. 2013
    ..The purpose of this prospective study was to identify risk factors for adverse outcomes or increased resource utilization after abdominal cancer surgery in geriatric patients...
  23. doi request reprint Tumor-node-metastasis staging of pancreatic adenocarcinoma
    Matthew H G Katz
    Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:111-25. 2008
    ....
  24. doi request reprint Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer
    Hop S Tran Cao
    Department of Surgery, University of California at San Diego, California, USA
    Mol Cancer Ther 9:2068-78. 2010
    ..Our results suggest the potential of this therapeutic paradigm against pancreatic cancer in the adjuvant and maintenance settings...
  25. doi request reprint Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design
    Matthew H G Katz
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:2787-95. 2013
    ..Shortcomings have included an absence of staging and treatment standards and pre-existing biases with regard to the use of neoadjuvant therapy and the role of vascular resection at pancreatectomy...
  26. doi request reprint Current diagnosis and management of unusual pancreatic tumors
    Melinda M Mortenson
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg 196:100-13. 2008
    ....
  27. pmc Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors
    Christine S Landry
    Department of Surgical Oncology, Baylor University Medical Center, 3410 Worth Street, Suite 235, Dallas, TX 75246, USA
    World J Surg 37:1695-700. 2013
    ..We hypothesized that the extent of lymphadenectomy reported in a large administrative database would be associated with overall survival for jejunal and ileal neuroendocrine tumors...
  28. ncbi request reprint Associated vascular injury in patients with bile duct injury during cholecystectomy
    Alex M Keleman
    University of California, Irvine Medical Center, Orange, California, USA
    Am Surg 77:1330-3. 2011
    ....
  29. pmc Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C
    Laura A Lambert
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:2181-7. 2009
    ..This study analyzes the incidence and risk factors for developing neutropenia following MMC-HIPEC combined with CRS...
  30. doi request reprint Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy
    Richard N Berri
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4008, USA
    J Am Coll Surg 214:778-87. 2012
    ..We hypothesized that sequential measurement of currently available serum proteins will indicate fluid balance...
  31. ncbi request reprint Current concepts in multimodality therapy for retroperitoneal sarcoma
    Matthew H G Katz
    The University of Texas, MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:159-68. 2007
    ....
  32. doi request reprint Treatment of borderline resectable pancreatic cancer
    Amanda B Cooper
    MD Anderson Cancer Center, 1400 Pressler Dr, Houston, TX, USA
    Curr Treat Options Oncol 14:293-310. 2013
    ..Coordination among a multidisciplinary team of physicians is necessary to maximize these complex patients' short- and long-term oncologic outcomes...
  33. ncbi request reprint Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis
    Matthew H G Katz
    Department of Surgery, University of California San Diego, San Diego, California 92103, USA
    Hepatogastroenterology 51:842-6. 2004
    ..This study investigates histopathologic factors that contribute to the superior outcome of these patients...